|
|
|
| Effects of Crimomycin Combined with Moxifloxacin Intrathoracic Injection on the Serum and Pleural Effusion Interferon-γ TNF-α CEA and ADA Levels of Patients with Tuberculous Pleurisy |
| TAO Guanyu, et al |
| Dazhou Integrated Traditional Chinese and Western Medicine Hospital, Sichuan Dazhou 635000, China |
|
|
|
|
Abstract Objective: To research the effect of crimomycin combined moxifloxacin intrathoracic injection on the serum and pleural effusion interferon-γ(IFN-γ), tumor necrosis factor-α(TNF-α), carcinoembryonic antigen (CEA), adenosine deaminase (ADA) levels of patients with tuberculous pleurisy. Methods: 98 cases of patients with tuberculous pleurisy admitted to our hospital from April 2013 to April 2016 were selected and randomly divided into two groups, the control group was treated with crimomycin, while the experimental group was treated with moxifloxacin based on the control group. The clinical curative effect, changes of serum and pleural effusion IFN-γ, TNF-α, CEA, ADA, forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), pleural thickness levels before and after treatment and incidence of adverse reactions were compared between two groups. Results: The total effective rate of experimental group was higher than that of the control group (P<0.05). Serum and pleural effusion IFN-γ, FVC and FEV1 in two groups were significantly higher than those before treatment, and the above indexes were significantly higher in the experimental group than in the control group. Serum TNF- α, CEA, ADA and pleural thickness in two groups were significantly lower than before treatment, and the above indexes were significantly lower than those in the control group. There were statistically significant differences in the interactions between the two groups, between different time points, between groups, and between different time points (P<0.05). There was no statistically significant difference between the two groups (P>0. 05). Conclusion: The curative effect of crimomycin combined moxifloxacin intrathoracic injection was bettetr than monocolomycin alone with tuberculous pleurisy patients in the treatment of patients with tuberculous pleurisy, whcih can effectively regulate the serum and pleural effusion levels of interferon-γ, TNF-α, CEA, ADA.
|
|
|
|
|
|
[1] 何丽美,赵子文.联合检测ADA、CEA和CYFRA21-1对鉴别结核性和恶性胸腔积液的诊断价值[J].热带医学杂志,2015,15(7):914~916.
[2] 张东芳,张琴.结核性胸膜炎治疗研究进展[J].职业与健康,2016,32(8):1143~1145.
[3] 陈效友.结核性胸膜炎诊疗进展[J].临床内科杂志,2015,32(10):51~55.
[4] 黄娟,雍小兰,陈章,等.莫西沙星在结核性胸膜炎患者体内的药动学及胸膜透过性[J].中国新药与临床杂志,2017,36(4):234~238.
[5] 王巍,庄玉辉.结核性胸膜炎的诊断和治疗[J].中国防痨杂志,2001,23(5):312~316.
[6] 周清平,尹玲,陈雯,等.常规抗结核联合异烟肼、地塞米松胸腔内注射治疗结核性胸膜炎的临床疗效分析[J].中南医学科学杂志,2017,45(4):385~387.
[7] 张春晓,王永亮,崔俊伟,等.左氧氟沙星与卷曲霉素联合治疗耐多药肺结核的疗效观察[J].中华医院感染学杂志,2016,26(9):1936~1938.
[8] 王晓红,李勋光.莫西沙星强化治疗结核性胸膜炎疗效观察[J].国际呼吸杂志,2017,37(10):737~739.
[9] 李洪智.莫西沙星与卷曲霉素对肺结核患者血清IL-1、IL-6、IL-17、TNF-α变化的影响及临床治疗效果[J].临床肺科杂志,2017,22(7):1180~1183.
[10] 黄晓磊,宋晓东,张娜,等.胸腔积液ADA、IFN-γ、TNF-α与胸腔积液沉渣DNA联合检测在结核性胸膜炎诊断中的价值[J].检验医学与临床,2017,14(1):24~26. |
|
|
|
2018, Vol. 24 
